NTRA News and Press, Natera Inc. From 10/06/23

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Natera, Inc. (NasdaqGS: NTRA). On March 14, 2022, a jury found that the Company intentionally...

Test performance showed 82% pre-treatment detection, with 100% longitudinal sensitivity and 100% longitudinal specificity to disease progression Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a new study published in Frontiers in Oncology ...

2023-10-03 18:04:45 ET More on Natera, CareDx Natera: Strong Growth Amidst Profitability Challenges CareDx wins injunction against Natera in false advertising case Natera announces $250M common stock offering For further details see: Natera prevails in pa...

Final decision follows multiple previous court rulings in favor of Natera and upholds invalidation of CareDx patents Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced that the United States Supreme Court denied CareDx, Inc.’s (NASD...

Lays groundwork for multiple submissions across cancer types, starting with CDx label in bladder cancer Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the submission of the first module of its premarket approval (PMA) application to the U....

2023-10-01 16:02:12 ET Bernstein is bullish on medtech stocks Thermo Fisher, Guardant Health, Revvity and PacBio, but sees further downside for Illumina, according to a new industry note. The investment firm kicked off coverage of the US life science tools and diagnostics sector last we...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced three appointments within its senior leadership team, effective immediately. Solomon Moshkevich has been promoted to president of clinical diagnostics and will lead Natera’s team of general manag...

Prospective study to monitor 600 patients in real time, across all subtypes of breast cancer Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a new study as part of the I-SPY 2 trial, sponsored and operated by Quantum Leap Healthcare Collaborati...

2023-09-07 05:46:15 ET More on Natera Financial information for Natera Natera: Strong Growth Amidst Profitability Challenges Natera announces $250M common stock offering CareDx wins injunction against Natera in false advertising case For further detai...

Natera, Inc. (Nasdaq: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced the pricing of its underwritten public offering of 4,550,000 shares of its common stock at a price to the public of $55.00 per share. Closing of the offering is expected to occur on September 11, 2023, ...